Table 4 Selected haematologic, hepatic and renal toxicities (according to NCI-CTC criteria) in all mapatumumab-treated patients (n=38)

From: Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

 

Grade 0, n (%)

Grade 1, n (%)

Grade 2, n (%)

Grade 3, n (%)

Grade 4, n (%)

Leukocytes

32 (84)

5 (13)

1 (3)

—

—

Neutrophils (ANC)

33 (87)

4 (11)

1 (3)

—

—

Lymphocytes

22 (58)

—

12 (32)

3 (8)

1 (3)

Platelets

36 (95)

—

2 (5)

—

—

Haemoglobin

11 (29)

16 (42)

10 (26)

1 (3)

—

AST

12 (32)

13 (34)

8 (21)

4 (11)

1 (3)

ALT

21 (55)

11 (29)

5 (13)

—

—

Total bilirubin

29 (77)

3 (8)

5 (13)

—

1 (3)

Creatinine

24 (63)

8 (21)

5 (13)

—

1 (3)

  1. Abbreviations: ANC=absolute neutrophil count; ALT=alanine transaminase; AST=aspartate transaminase.
Back to article page